OUR TEAM | Core Members

MARKETS & LISTING is built on a solid foundation. We count on more than a dozen contributors for their knowledge and experience to this endeavour. It was created from the outside-in, following our founding partners’ ability to read into the uncertain realities and needs of biotech companies, but it has grown from the inside-out, thanks to the steady effort from each core member of the team consistently acting as a catalytic force.

                       | Senior Members

MARKETS & LISTING is home to a diverse council of seasoned professionals in the life sciences sector: knowledge experts, industry scholars, and entrepreneurs brought together by their will to do more, to create more. Each one of them brings a past full of experience and recognition as well as a present marked by a variety of responsibilities and obligations in current active markets and fronts, even outside of MARKETS & LISTING. All our team members share the common goal of building a better biotech ecosystem, coupled with a common culture of dynamic and evolving organization. To solve our clients’ unique and ever-changing puzzles, they compose, case after case, the missing piece.

Drittanti, Lila

Founding Partner at MARKETS & LISTING

Lila (PhD) is a seasoned professional with an extensive scientific background. She’s been a fellow and researcher for CONICET (Argentina), DAAD (Germany), INSERM (France) and NIH (USA) in molecular and cell biology, virology and immunology. She has 25 years of experience leading and advising operations (early product development, regulatory and development plans, team building and management, organisation, quality and compliance, among others) in life sciences and healthcare companies. Lila was the co-founder of Nautilus Biotech (France) an innovative biotech dedicated to 2nd-generation therapeutic proteins and between 1999 and 2008 she was Nautilus' CSO and COO. During that time several R&D internal and external projects (Aventis Pasteur (France), Serono (Switzerland), Wyeth (USA)) were performed and a family of more than 100 patents were submitted. Before Nautilus, she was Recherche Groupe Leader at Genethon (France), in charge of the development of innovative technologies for AAV vector production. Between 2009 and 2015 she was an Active Partner at L&M Crecer (Argentina, France) where she advised clients from the medical services and industry sectors on product development, operations, and regulatory compliance. Since 2015, she is a Founding Partner at MARKETS & LISTING where she is responsible for managing MARKETS & LISTING’s client missions for all high-level accounts.

+
-

Lila (PhD) is a seasoned professional with an extensive scientific background. She’s been a fellow and researcher for CONICET (Argentina), DAAD (Germany), INSERM (France) and NIH (USA) in molecular and cell biology, virology and immunology. She has 25 years of experience leading and advising operations (early product development, regulatory and development plans, team building and management, organisation, quality and compliance, among others) in life sciences and healthcare companies. Lila was the co-founder of Nautilus Biotech (France) an innovative biotech dedicated to 2nd-generation therapeutic proteins and between 1999 and 2008 she was Nautilus' CSO and COO. During that time several R&D internal and external projects (Aventis Pasteur (France), Serono (Switzerland), Wyeth (USA)) were performed and a family of more than 100 patents were submitted. Before Nautilus, she was Recherche Groupe Leader at Genethon (France), in charge of the development of innovative technologies for AAV vector production. Between 2009 and 2015 she was an Active Partner at L&M Crecer (Argentina, France) where she advised clients from the medical services and industry sectors on product development, operations, and regulatory compliance. Since 2015, she is a Founding Partner at MARKETS & LISTING where she is responsible for managing MARKETS & LISTING’s client missions for all high-level accounts.

Leopold, Marie-Hélène

Knowledge Expert at MARKETS & LISTING

Currently active as founding CEO at HealthTech Advisory, Paris

Marie-Hélène is a Certified International Investment Analyst with 35 years of experience in Equity Research in the Pharma and Healthcare sectors. She has headed the sell-side Pharma & Biotech analyst team at different Investment banks (Paribas Capital Markets, BNP Paribas and SG Cowen). In addition to analysing her publicly-traded portfolio of stocks, she was often responsible for the analysis and valuation of many companies seeking an IPO. She also worked for operations like M&As to provide strategic rationale, value analysis and valuation outputs for the CEO and CFO of the acquirer. From 2007 to 2018, she was the Global Pharma & Healthcare head analyst at Amundi Asset Management (the largest asset manager in Europe with > 1,500bn€ under management); responsible for recommending ideas to invest in. Over that period, she had on average 5-6 one-on-one meetings per year with each CEO, CFO or CSO for her stock coverage of 50 companies (US & Europe) from very-large to medium-sized caps. In addition, she provided support for the Amundi’s Small and Mid-Cap team with the analysis of future transactions. During her tenure at Amundi, she was consistently voted among the top-3 analysts in Europe in the prestigious Extel ranking and many times #1 analyst in Pharma.

+
-

Marie-Hélène is a Certified International Investment Analyst with 35 years of experience in Equity Research in the Pharma and Healthcare sectors. She has headed the sell-side Pharma & Biotech analyst team at different Investment banks (Paribas Capital Markets, BNP Paribas and SG Cowen). In addition to analysing her publicly-traded portfolio of stocks, she was often responsible for the analysis and valuation of many companies seeking an IPO. She also worked for operations like M&As to provide strategic rationale, value analysis and valuation outputs for the CEO and CFO of the acquirer. From 2007 to 2018, she was the Global Pharma & Healthcare head analyst at Amundi Asset Management (the largest asset manager in Europe with > 1,500bn€ under management); responsible for recommending ideas to invest in. Over that period, she had on average 5-6 one-on-one meetings per year with each CEO, CFO or CSO for her stock coverage of 50 companies (US & Europe) from very-large to medium-sized caps. In addition, she provided support for the Amundi’s Small and Mid-Cap team with the analysis of future transactions. During her tenure at Amundi, she was consistently voted among the top-3 analysts in Europe in the prestigious Extel ranking and many times #1 analyst in Pharma.

Vega, Manuel

Founding Partner at MARKETS & LISTING

Manuel is a scientist by education, and at heart. He’s been a fellow and researcher for CONICET (Argentina), Würzburg University (Germany), Hosp. Henri Mondor/INSERM (France) and TNO (Netherlands), in molecular virology and gene therapy. After 10 years of scientific research mostly in disruptive subjects he turned to become a serial entrepreneur in biotechnology, leading over the last 20 years projects that would today be considered as deep biotech. Between 1999 and 2008 he was the co-founder and CEO of Nautilus Biotech (France) and Nautilus Technologies (USA), a biotech dedicated to 2nd-generation therapeutic proteins. Nautilus closed 4 rounds of VC investment and signed significant out-licensing deals on Nautilus’ products with worldwide leaders like Aventis Pasteur (France), Serono (Switzerland), Wyeth (USA) and Hanall Pharmaceuticals (South Korea). Nautilus Biotech’ and Nautilus Technologies’ assets were sold to Hanall Pharmaceuticals and to Catalyst Biosciences (USA), respectively, in 2009. Before Nautilus, he was Director of Development & Production at Genethon (France), at the time Genethon started its focus on gene therapy and vectorology. From 2009 to 2015 was an independent consultant to a number of life sciences companies and incubators. Since 2015, he has been a Founding Partner at MARKETS & LISTING.

+
-

Manuel is a scientist by education, and at heart. He’s been a fellow and researcher for CONICET (Argentina), Würzburg University (Germany), Hosp. Henri Mondor/INSERM (France) and TNO (Netherlands), in molecular virology and gene therapy. After 10 years of scientific research mostly in disruptive subjects he turned to become a serial entrepreneur in biotechnology, leading over the last 20 years projects that would today be considered as deep biotech. Between 1999 and 2008 he was the co-founder and CEO of Nautilus Biotech (France) and Nautilus Technologies (USA), a biotech dedicated to 2nd-generation therapeutic proteins. Nautilus closed 4 rounds of VC investment and signed significant out-licensing deals on Nautilus’ products with worldwide leaders like Aventis Pasteur (France), Serono (Switzerland), Wyeth (USA) and Hanall Pharmaceuticals (South Korea). Nautilus Biotech’ and Nautilus Technologies’ assets were sold to Hanall Pharmaceuticals and to Catalyst Biosciences (USA), respectively, in 2009. Before Nautilus, he was Director of Development & Production at Genethon (France), at the time Genethon started its focus on gene therapy and vectorology. From 2009 to 2015 was an independent consultant to a number of life sciences companies and incubators. Since 2015, he has been a Founding Partner at MARKETS & LISTING.

Cozzi, Guerrino

Knowledge Expert at MARKETS & LISTING

Currently active as Independent Advisor on Human Resources and Organizational Development

Born in Italy, Guerrino graduated in Economics at the University of Turin. He began his professional activity in the telecommunication industry, where, after an initial period in Finance, moved into Human Resources management. His international background and experience started with Ferrero, the candy and snack conglomerate. He joined Serono, the biotech/pharmaceutical company, in 1982 - at the Headquarters in Geneva, Switzerland - where he was given the opportunity to build an international career, covering all facets of Human Resources, on a worldwide basis. His last position with Serono was Senior Vice President Human Resources for the Group. In February 2000, he joined GEA, the management consulting firm, where he continued to develop his professional, international activity, in Human Resources and Organizational Development and Management topics. He now partners with selected associates like MARKETS & LISTING for specific missions. Guerrino is used to multicultural environments, which have equipped him with a high degree of sensitivity to diversity. His career enabled him to learn to manage complex or changing human resources environments and to develop a natural ability to adapt to differing situations and cultures.

+
-

Born in Italy, Guerrino graduated in Economics at the University of Turin. He began his professional activity in the telecommunication industry, where, after an initial period in Finance, moved into Human Resources management. His international background and experience started with Ferrero, the candy and snack conglomerate. He joined Serono, the biotech/pharmaceutical company, in 1982 - at the Headquarters in Geneva, Switzerland - where he was given the opportunity to build an international career, covering all facets of Human Resources, on a worldwide basis. His last position with Serono was Senior Vice President Human Resources for the Group. In February 2000, he joined GEA, the management consulting firm, where he continued to develop his professional, international activity, in Human Resources and Organizational Development and Management topics. He now partners with selected associates like MARKETS & LISTING for specific missions. Guerrino is used to multicultural environments, which have equipped him with a high degree of sensitivity to diversity. His career enabled him to learn to manage complex or changing human resources environments and to develop a natural ability to adapt to differing situations and cultures.

El Bougrini, Jamila

Knowledge Expert at MARKETS & LISTING

Currently active as Financial Analyst at Invest Securities, Paris

Jamila is a Financial Analyst dedicated to the Healthtech and Biotech sectors. She worked in several boutiques and Investment banks as a sell-side Equity Research Analyst such as Aurgalys, Bryan Garnier, Gilbert Dupont and Invest Securities. As part of her work, Jamila had the opportunity to analyse and provide valuation analysis for many private companies seeking for fundings, an IPO or a new strategy. She has a good understanding of healthcare issues and medical trends in France and Europe, as well as in the US. Jamila is often in contact with CEOs, CFOs and CSOs of the listed companies she has under coverage (from 12 to 18), but also with the management of peers and private companies. She has been ranked #1 analyst in Biotechnology in 2019 (France), and #3 in 2020 (Europe) in the Starmine ranking. Before joining the financial world in 2015, Jamila worked as a Scientific Officer in the research funding field within two renowned institutions: Fondation ARC pour la Recherche sur le Cancer (national foundation dedicated to cancer research) and Vaincre la Mucoviscidose (Cystic Fibrosis national association). She holds a PhD in Cellular and Molecular Biology from University of Orsay (Paris – 2009), and a MBA from University of Dauphine / IAE of Sorbonne (Paris – 2015).

+
-

Jamila is a Financial Analyst dedicated to the Healthtech and Biotech sectors. She worked in several boutiques and Investment banks as a sell-side Equity Research Analyst such as Aurgalys, Bryan Garnier, Gilbert Dupont and Invest Securities. As part of her work, Jamila had the opportunity to analyse and provide valuation analysis for many private companies seeking for fundings, an IPO or a new strategy. She has a good understanding of healthcare issues and medical trends in France and Europe, as well as in the US. Jamila is often in contact with CEOs, CFOs and CSOs of the listed companies she has under coverage (from 12 to 18), but also with the management of peers and private companies. She has been ranked #1 analyst in Biotechnology in 2019 (France), and #3 in 2020 (Europe) in the Starmine ranking. Before joining the financial world in 2015, Jamila worked as a Scientific Officer in the research funding field within two renowned institutions: Fondation ARC pour la Recherche sur le Cancer (national foundation dedicated to cancer research) and Vaincre la Mucoviscidose (Cystic Fibrosis national association). She holds a PhD in Cellular and Molecular Biology from University of Orsay (Paris – 2009), and a MBA from University of Dauphine / IAE of Sorbonne (Paris – 2015).

Dombu, Christophe

Knowledge Expert at MARKETS & LISTING

Currently active as sell-side Analyst at Portzamparc, BNP Paribas, Paris

Christophe is a Sell-side Analyst at Portzamparc (BNP Parisbas Group), where he is in charge of the team of analysts dedicated to the Life Science sector. In particular, he monitors Equity research on a portfolio of ~30 European Biotech and Medtech companies and participates in primary and secondary market operations. Since 2018, he has collaborated with M&L where he brings his expertise for the strategic advisory of early/mid stage non listed companies. Christophe holds a PhD in Nanomedicine from the University of Lille 2 and an Advanced Master's degree in Biopharmaceutical Business Management.

+
-

Christophe is a Sell-side Analyst at Portzamparc (BNP Parisbas Group), where he is in charge of the team of analysts dedicated to the Life Science sector. In particular, he monitors Equity research on a portfolio of ~30 European Biotech and Medtech companies and participates in primary and secondary market operations. Since 2018, he has collaborated with M&L where he brings his expertise for the strategic advisory of early/mid stage non listed companies. Christophe holds a PhD in Nanomedicine from the University of Lille 2 and an Advanced Master's degree in Biopharmaceutical Business Management.

Malcoiffe, David

Knowledge Expert at MARKETS & LISTING

Currently active as Corporate Partner at B&B, Paris

David is a Corporate Partner at BIRD & BIRD (B&B). He advises B&B clients on private equity transactions, M&A and joint ventures. With training and expertise in both corporate and tax law, he assists purchasers and sellers in national and international M&A transactions. He also advises investment funds and start-ups in private equity and venture capital transactions, including the drafting and negotiation of term sheets, share and asset purchase agreements, investment and shareholders’ agreements, joint venture and merger agreements and the coordination and undertaking of due diligence procedures internationally. B&B has extensive experience in domestic and cross-border mergers and acquisitions, advising a large variety of companies, ranging from multinationals to small and medium-sized companies. B&B is recognised internationally as an undisputed market leader in the M&A sector and B&B’s team includes a significant number of lawyers acknowledged as leading individuals in the M&A field. As a truly international firm of 1,300 lawyers, located throughout 30 integrated offices worldwide, B&B offers a perfectly integrated service that combines local expertise with the capacity for global action.‍

+
-

David is a Corporate Partner at BIRD & BIRD (B&B). He advises B&B clients on private equity transactions, M&A and joint ventures. With training and expertise in both corporate and tax law, he assists purchasers and sellers in national and international M&A transactions. He also advises investment funds and start-ups in private equity and venture capital transactions, including the drafting and negotiation of term sheets, share and asset purchase agreements, investment and shareholders’ agreements, joint venture and merger agreements and the coordination and undertaking of due diligence procedures internationally. B&B has extensive experience in domestic and cross-border mergers and acquisitions, advising a large variety of companies, ranging from multinationals to small and medium-sized companies. B&B is recognised internationally as an undisputed market leader in the M&A sector and B&B’s team includes a significant number of lawyers acknowledged as leading individuals in the M&A field. As a truly international firm of 1,300 lawyers, located throughout 30 integrated offices worldwide, B&B offers a perfectly integrated service that combines local expertise with the capacity for global action.‍

Coulter, Ivan

Knowledge Expert at MARKETS & LISTING

Currently active as Managing Director at Eden BioPharma Ltd, NovaUCD Belfield Innovation Park, Dublin

Dr. Ivan Coulter has extensive experience in key aspects of innovation, product and corporate development within the biotech sector. Key areas of expertise include business and strategic planning, fund-raising, IP strategy and execution, and business development. Ivan has led translational research, clinical study design and execution, established GMP facilities, assembled scientific and clinical advisory boards. Ivan founded Sigmoid Pharma (Sublimity) to develop products to treat gastrointestinal and autoimmune diseases. Sigmoid’s lead product for the treatment of ulcerative colitis is in Phase IIb. Under Ivan’s leadership, Sigmoid raised €100M and concluded licensing deals. Ivan is the lead inventor on multiple patents spanning technologies, products and platforms. Ivan holds a BSc. (Hons.) degree in Pharmacology and a PhD in Cancer Research/Genetics from University College Dublin, was a Postdoctoral Fellow at the Institut Curie, Paris. Research topics included the utilization of antisense oligonucleotides, viral vectors and transposons to modulate gene and cell function. Ivan obtained a Certified Diploma in Accounting and Finance from the ACCA, received his MBA from the Johnson School of Graduate Management, Cornell University, USA as well as a Diploma in Corporate Governance.

+
-

Dr. Ivan Coulter has extensive experience in key aspects of innovation, product and corporate development within the biotech sector. Key areas of expertise include business and strategic planning, fund-raising, IP strategy and execution, and business development. Ivan has led translational research, clinical study design and execution, established GMP facilities, assembled scientific and clinical advisory boards. Ivan founded Sigmoid Pharma (Sublimity) to develop products to treat gastrointestinal and autoimmune diseases. Sigmoid’s lead product for the treatment of ulcerative colitis is in Phase IIb. Under Ivan’s leadership, Sigmoid raised €100M and concluded licensing deals. Ivan is the lead inventor on multiple patents spanning technologies, products and platforms. Ivan holds a BSc. (Hons.) degree in Pharmacology and a PhD in Cancer Research/Genetics from University College Dublin, was a Postdoctoral Fellow at the Institut Curie, Paris. Research topics included the utilization of antisense oligonucleotides, viral vectors and transposons to modulate gene and cell function. Ivan obtained a Certified Diploma in Accounting and Finance from the ACCA, received his MBA from the Johnson School of Graduate Management, Cornell University, USA as well as a Diploma in Corporate Governance.

Czaplicki, Dominik

Knowledge Expert at MARKETS & LISTING

Currently active as Investment Manager at ABAN Fund, Krakow

Dominik has a scientific background in biotechnology, biochemistry and molecular biology. Currently responsible for scouting and evaluation of early-stage investment opportunities for a Polish seed fund operating in a public-private model. For a number of years affiliated with the Jagiellonian University in Krakow - the leading university in Poland, where he worked in different roles including technology transfer officer, post-doc researcher, academic teacher and finally - industrial liaison officer, seeking for collaboration partners in small and mid-sized biotech and pharma. He is also a patent engineer, involved in drafting and translating applications, with additional experience in patent procedures (Polish, PCT, EPO). Previously, involved in NGO projects related to science education and vocational training. Dominik holds a Ph.D. in cancer research from the Jagiellonian University in Krakow. In 2012 he completed an MBA-type executive training at the University of California, Berkeley as part of the Top500 Innovators programme run by the Polish Ministry of Science.

+
-

Dominik has a scientific background in biotechnology, biochemistry and molecular biology. Currently responsible for scouting and evaluation of early-stage investment opportunities for a Polish seed fund operating in a public-private model. For a number of years affiliated with the Jagiellonian University in Krakow - the leading university in Poland, where he worked in different roles including technology transfer officer, post-doc researcher, academic teacher and finally - industrial liaison officer, seeking for collaboration partners in small and mid-sized biotech and pharma. He is also a patent engineer, involved in drafting and translating applications, with additional experience in patent procedures (Polish, PCT, EPO). Previously, involved in NGO projects related to science education and vocational training. Dominik holds a Ph.D. in cancer research from the Jagiellonian University in Krakow. In 2012 he completed an MBA-type executive training at the University of California, Berkeley as part of the Top500 Innovators programme run by the Polish Ministry of Science.